| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.5M | +72.7% | +283.0% |
| SG&A Expense | $11.4M | +83.2% | +1331.6% |
| Operating Income | -$15.9M | -80.2% | -726.9% |
| Net Income | -$156.7M | -9.9% | — |
| EPS (Basic) | -$1.64 | -6.5% | -5366.7% |
| EPS (Diluted) | -$1.64 | -6.5% | -5366.7% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $257.6M | +111.5% | — |
| Current Assets | $258.9M | +109.5% | — |
| Total Assets | $323.3M | +79.9% | +20.0% |
| Current Liabilities | $15.7M | +91.8% | +475.1% |
| Total Liabilities | $368.6M | +28.7% | +2229.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$21.1M | — | — |
| Investing Cash Flow | -$13.4M | — | — |
| Financing Cash Flow | $275.3M | — | — |
| -$58.6M |
| +55.6% |
| -275.4% |